Kyle Blankenship – Page 5 – Endpoints News

about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship

Kyle Blankenship on LinkedIn

author articles

Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a ...

4 years ago

Deciphera's TKI drug flops key test in earlier-line GI tumors, sending stock into a tailspin

4 years ago

Fresh off corporate split, bluebird bio plots new hybrid headquarters at Somerville's Assembly Row

4 years ago

Alphabet kickstarts new AI drug discovery outfit with lessons learned from DeepMind protein breakthroughs

4 years ago

More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward

4 years ago

Weeks into first approval, Cara waves goodbye to founding CEO in favor of board member

4 years ago

Flagship and the Cystic Fibrosis Foundation team up on a novel research pact to chase down potential cures

4 years ago

Weeks into CEO shakeup, Mirati bids adieu to a pair of C-suiters with KRAS drug filing around the corner

4 years ago

Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail

4 years ago

Angion's organ damage drug strikes out again, this time in high-risk kidney transplant patients

4 years ago

A combo of AstraZeneca's Imfinzi and chemo wins where others have failed in pivotal biliary tract test

4 years ago

Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush

4 years ago

Incyte yanks EU application for PD-1 drug, citing inability to answer regulators' 'major concerns'

4 years ago

Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut

4 years ago

Eli Lilly bags FDA nod for Verzenio in early breast cancer, but a controversial diagnostic could dog its rollout

4 years ago

Inside the deal: As leaked details goosed its stock, Acceleron's CEO pumped Merck for more cash

4 years ago

J&J science lead Paul Stoffels set to retire amid brain trust shakeup at world's largest drugmaker

4 years ago

Flexion heads to the discount aisle for a $450M+ merger with Pacira

4 years ago

Relay unrolls early data for anti-FGFR drug it thinks stand alone in terms of safety profile

4 years ago

Bristol Myers' TYK2 drug bombs ulcerative colitis test, but hopes are still high with psoriasis filing on deck

4 years ago

A short-sell attack sends Ginkgo's share price spinning, underscoring investors' concerns over synbio field

4 years ago

Enanta culls internal NASH work, betting on an out-licensing strategy in the disaster-strewn field

4 years ago

J&J signs on Xencor for a $100M licensing deal targeting CD20, looking to press its advantage in bispecifics

4 years ago

Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

4 years ago

First page Previous page 2 3 456 7 8 Next page Last page